Reeling from Covid flop, Icosavax says its RSV candidate passed early test. But investors need some more convincing

Amber Tong

Three months separated from a disappointing readout of its Covid-19 vaccine, Icosavax is back with what it calls positive topline data for a different VLP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reeling from Covid flop, Icosavax says its RSV candidate passed early test. But investors need some more convincing

Amber Tong

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?

Reel­ing from Covid flop, Icosavax says its RSV can­di­date passed ear­ly test. But in­vestors need some more con­vinc­ing

Amber Tong

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Reeling from Covid flop, Icosavax says its RSV candidate passed early test. But investors need some more convincing

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?